STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Belite Bio (BLTE) Form 144 Filed for 30,000 ADS Sale on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans to sell 30,000 ADS valued at $1.9M after exercising options; transaction is routine but noteworthy for share supply.

The filing documents a proposed sale of 30,000 ADS acquired by stock option exercise on 03/07/2025 and scheduled for sale on 08/21/2025 through J.P. Morgan Securities LLC. This records an increase in potential public float of the issuer by 30,000 ADS. The filing does not disclose the identity of the selling person, the filers holdings after the sale, or any trading plan adoption date. As provided, there are no reported sales in the prior three months for the account named.

TL;DR: Form 144 appears to follow Rule 144 disclosure for an option exercise and proposed sale; no compliance exceptions noted in the form itself.

The notice supplies the required elements for a Rule 144 filing: class of security, broker name and address, number of shares, aggregate market value, acquisition date and nature (stock option exercise), payment method (cash), and proposed sale date and exchange. The filer affirms they are not aware of undisclosed material adverse information. The form does not include a stated Rule 10b5-1 plan adoption date or signature block details in the provided content.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the BLTE Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 30,000 ADS valued at $1,902,600 via J.P. Morgan Securities LLC on NASDAQ, with an approximate sale date of 08/21/2025.

How and when were the securities being sold acquired?

The 30,000 ADS were acquired on 03/07/2025 through a stock option exercise, with payment made in cash on the same date.

Does the filing report any sales in the past three months by the same person?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker is handling the proposed sale?

The broker listed is J.P. Morgan Securities LLC, located at 390 Madison Avenue, 6th Floor, New York, NY 10017.

Does the filer assert knowledge of any undisclosed material information?

By signing the notice, the person for whose account the securities are to be sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Belite Bio, Inc

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Latest SEC Filings

BLTE Stock Data

4.52B
17.29M
50.45%
0.7%
0.55%
Biotechnology
Healthcare
Link
United States
San Diego